Literature DB >> 19001041

Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy.

Joanne E Mallinson1, Dumitru Constantin-Teodosiu, James Sidaway, F Russell Westwood, Paul L Greenhaff.   

Abstract

Statins are used clinically for cholesterol reduction, but statin therapy is associated with myopathic changes through a poorly defined mechanism. We used an in vivo model of statin myopathy to determine whether statins up-regulate genes associated with proteasomal- and lysosomal-mediated proteolysis and whether PDK gene expression is simultaneously up-regulated leading to the impairment of muscle carbohydrate oxidation. Animals were dosed daily with 80 mg kg(-1) day(-1) simvastatin for 4 (n = 6) and 12 days (n = 5), 88 mg kg(-1) day(-1) simvastatin for 12 days (n = 4), or vehicle (0.5% w/v hydroxypropyl-methylcellulose and 0.1% w/v polysorbate 80; Control, n = 6) for 12 days by oral gavage. We found, in biceps femoris muscle, decreased Akt(Ser473), FOXO1(Ser253) and FOXO3a(Ser253) phosphorylation in the cytosol (P < 0.05, P < 0.05, P < 0.001, respectively) and decreased phosphorylation of FOXO1 in the nucleus after 12 days simvastatin when compared to Control (P < 0.05). This was paralleled by a marked increase in the transcription of downstream targets of FOXO, i.e. MAFbx (P < 0.001), MuRF-1 (P < 0.001), cathepsin-L (P < 0.05), PDK2 (P < 0.05) and PDK4 (P < 0.05). These changes were accompanied by increased PPARalpha (P < 0.05), TNFalpha (P < 0.01), IL6 (P < 0.01), Mt1A (P < 0.01) mRNA and increased muscle glycogen (P < 0.05) compared to Control. RhoA activity decreased after 4 days simvastatin (P < 0.05); however, activity was no different from Control after 12 days. Simvastatin down-regulated PI3k/Akt signalling, independently of RhoA, and up-regulated FOXO transcription factors and downstream gene targets known to be implicated in proteasomal- and lysosomal-mediated muscle proteolysis, carbohydrate oxidation, oxidative stress and inflammation in an in vivo model of statin-induced myopathy. These changes occurred in the main before evidence of extensive myopathy or a decline in the muscle protein to DNA ratio.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19001041      PMCID: PMC2670035          DOI: 10.1113/jphysiol.2008.164699

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  54 in total

Review 1.  Current overview of statin-induced myopathy.

Authors:  Robert S Rosenson
Journal:  Am J Med       Date:  2004-03-15       Impact factor: 4.965

Review 2.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

3.  Insulin/IGF-1 and TNF-alpha stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways.

Authors:  L Rui; V Aguirre; J K Kim; G I Shulman; A Lee; A Corbould; A Dunaif; M F White
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 4.  The mammalian pyruvate dehydrogenase complex: structure and regulation.

Authors:  O H Wieland
Journal:  Rev Physiol Biochem Pharmacol       Date:  1983       Impact factor: 5.545

5.  Fibrates and statins rapidly and synergistically induce pyruvate dehydrogenase kinase 4 mRNA in the liver and muscles of mice.

Authors:  Kiyoto Motojima; Kouichi Seto
Journal:  Biol Pharm Bull       Date:  2003-07       Impact factor: 2.233

6.  Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.

Authors:  Marco Sandri; Claudia Sandri; Alex Gilbert; Carsten Skurk; Elisa Calabria; Anne Picard; Kenneth Walsh; Stefano Schiaffino; Stewart H Lecker; Alfred L Goldberg
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

7.  The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.

Authors:  Dennis W Schneck; Bruce K Birmingham; Julie A Zalikowski; Patrick D Mitchell; Yi Wang; Paul D Martin; Kenneth C Lasseter; Colin D A Brown; Amy S Windass; Ali Raza
Journal:  Clin Pharmacol Ther       Date:  2004-05       Impact factor: 6.875

8.  Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression.

Authors:  Stewart H Lecker; R Thomas Jagoe; Alexander Gilbert; Marcelo Gomes; Vickie Baracos; James Bailey; S Russ Price; William E Mitch; Alfred L Goldberg
Journal:  FASEB J       Date:  2004-01       Impact factor: 5.191

Review 9.  Molecular mechanisms modulating muscle mass.

Authors:  David J Glass
Journal:  Trends Mol Med       Date:  2003-08       Impact factor: 11.951

10.  Forkhead transcription factor FOXO1 (FKHR)-dependent induction of PDK4 gene expression in skeletal muscle during energy deprivation.

Authors:  Tatsuo Furuyama; Kazuko Kitayama; Hitoshi Yamashita; Nozomu Mori
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

View more
  35 in total

1.  The battle to keep or lose skeletal muscle with ageing.

Authors:  Michael Kjaer; Jakob G Jespersen
Journal:  J Physiol       Date:  2009-01-15       Impact factor: 5.182

2.  Simvastatin represses protein synthesis in the muscle-derived C₂C₁₂ cell line with a concomitant reduction in eukaryotic initiation factor 2B expression.

Authors:  Alexander P Tuckow; Sarah J Jefferson; Scot R Kimball; Leonard S Jefferson
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-01-11       Impact factor: 4.310

Review 3.  Statins and diabetes: the good, the bad, and the unknown.

Authors:  Kelly Axsom; Jeffrey S Berger; Arthur Z Schwartzbard
Journal:  Curr Atheroscler Rep       Date:  2013-02       Impact factor: 5.113

4.  Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle.

Authors:  Annette Draeger; Verónica Sanchez-Freire; Katia Monastyrskaya; Hans Hoppeler; Matthias Mueller; Fabio Breil; Markus G Mohaupt; Eduard B Babiychuk
Journal:  Am J Pathol       Date:  2010-05-20       Impact factor: 4.307

Review 5.  The effects of statin medications on aerobic exercise capacity and training adaptations.

Authors:  Zsolt Murlasits; Zsolt Radák
Journal:  Sports Med       Date:  2014-11       Impact factor: 11.136

Review 6.  Statin treatment, new-onset diabetes, and other adverse effects: a systematic review.

Authors:  Casper N Bang; Peter M Okin
Journal:  Curr Cardiol Rep       Date:  2014-03       Impact factor: 2.931

Review 7.  Statin use and risk of diabetes mellitus.

Authors:  Bharti Chogtu; Rahul Magazine; K L Bairy
Journal:  World J Diabetes       Date:  2015-03-15

8.  Ontogeny of proteolytic signaling and antioxidant capacity in fetal and neonatal diaphragm.

Authors:  Yong Song; J Jane Pillow
Journal:  Anat Rec (Hoboken)       Date:  2012-03-07       Impact factor: 2.064

Review 9.  Update on toxic myopathies.

Authors:  F L Mastaglia; M Needham
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

10.  Low-dose dexamethasone prevents endotoxaemia-induced muscle protein loss and impairment of carbohydrate oxidation in rat skeletal muscle.

Authors:  Hannah Crossland; Dumitru Constantin-Teodosiu; Paul L Greenhaff; Sheila M Gardiner
Journal:  J Physiol       Date:  2010-02-22       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.